ISACA
As a result of the continued growth and development over the last 50 years, ISACA, the global professional association advancing individuals and organizations in their pursuit of digital trust, is expanding its international reach and opening a new office in Dublin—its first European office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005075/en/
Chris Dimitriadis, Chief Global Strategy Officer at ISACA (Photo: Business Wire)
ISACA´s success is defined by the passion, hard work and commitment of its more than 165,000 members in more than 180 countries worldwide. In Europe, the organization has over 30,000 members working in information and cyber security, assurance, governance, risk and privacy from different industries such as Banking & Finance, Government, Telecommunications, Engineering, Public Accounting, Education, Retail, Health, FMCG, Automotive, Utilities, Food & Beverage among others.
ISACA in Europe combines the strength and scale of a large, multi-national organization with an expert, local knowledge of the market and professional communities ISACA serves. The new office intends to facilitate cooperation between European regions, chapters and members and strengthen ISACA’s capacity to collaborate with key public and private stakeholders, as well as enterprises and academia.
“Our expanded regional presence in Europe will provide services dedicated to Europe and help extend our global reach and impact,” said ISACA CEO David Samuelson. “ISACA is both a global and a local organization, and we want to serve our professional communities where they live and work. We are very excited to have a stronger local presence in Europe to better partner with European government, enterprises, universities and our members to advance digital trust.”
The office and ISACA’s new team members in Europe will build on the strong ties that already exist between regions by promoting investment, synergies and economic opportunities to benefit members and enterprises.
Ireland’s Minister of State for eGovernment Ossian Smyth said, “We welcome ISACA’s commitment and investment into Ireland. As we continue to develop Ireland as a European hub for the digital economy and as a cyber centre of excellence, it is crucial to continue to build an expert and diverse specialist ecosystem. ISACA’s pre-eminent global work on talent development, building the cyber profession and developing tools and frameworks to underpin the next phase of technology adoption in a safe and transparent manner, will be a boost to our tech scene. We look forward to ongoing cooperation with ISACA in improving cybersecurity preparedness and resilience.”
ISACA’s European presence is led by Chris Dimitriadis, Chief Global Strategy Officer at ISACA. Dimitriadis has deep industry and ISACA experience, having served as ISACA board chair and as a past chief information security officer at a global organization.
“ISACA has a long history in Europe, and we are incredibly proud of our chapters, volunteers, members and partners in the region,” said Dimitriadis. “We are excited to strengthen our support in the communities that we serve by establishing a team of highly experienced and reputable European professionals and by opening our first office in Dublin that will strategically coordinate and support our 45 chapters in Europe and our business, government and academic partners.”
ISACA, established in 1969, is widely known for its globally recognized certifications, including Certified Information Systems Auditor (CISA) and Certified Information Security Manager (CISM), and its industry-leading frameworks, including COBIT. Additional information is at www.isaca.org/.
About ISACA
ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA is a global professional association and learning organization that leverages the expertise of its more than 165,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality. It has a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for underresourced and underrepresented populations.
Twitter: www.twitter.com/ISACANews
LinkedIn: www.linkedin.com/company/isaca
Facebook: www.facebook.com/ISACAGlobal
Instagram: www.instagram.com/isacanews
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom